- The clinic is conducting an evaluation of the PURE EP(tm) System, a signal processing technology for cardiac arrhythmia treatments
- New installation follows
Mayo Clinic inFlorida that has been conducting patient cases with the technology sinceJanuary 2020
The 30-day clinical evaluation of the PURE EP(tm) System is being conducted by the cardiac electrophysiologists
“We are pleased to expand our installation to a new
To date, more than 660 patient cases have been conducted with the PURE EP(tm) System by over 40 physicians across nine clinical sites, including
About
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations54 Wilton Road , 2nd floorWestport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
Source:
2021 GlobeNewswire, Inc., source